AnodyneWiki

Lisuride

Lisuride
Lisuride
Molecular structure drawn from PubChem coordinates
Rotamer
[]
Conformer structure via 3Dmol.js
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
Molecular mass338.40 g/mol [1]
Solubility1.40e-01 g/L [1]
Predicted LogP2.7 [1]
Structural Identifiers
[]
Molecular formulaC20H26N4O
IUPAC name3-[(6aR,9S)-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
SMILESCCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C
InChIInChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1
InChIKeyBKRGVLQUQGGVSM-KBXCAEBGSA-N
CAS number18016-80-3
UNIIE0QN3D755O
PubChem CID28864
Pharmacokinetics[]
Elimination half-life2 hours
MetabolismHepatic
ExcretionRenal and biliary in equal amounts
Routes of administrationOral, Investigational: Subcutaneous implant, transdermal patch

Lisuride (also known as Lysuride, Lisurida, Lisuridum, Dopergin, N'-((8α)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea, Methylergol Carbamide, Lysurid, Urea, N'-((8α)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethyl-, Mesylate, Lisuride or Revanil 200) is a substance of the ergoline and amphetamine class.

Chemistry

 []

Lisuride is a single defined stereoisomer.

Lisuride matches Lipinski's rule of five.

Pharmacology

Mechanism of action []

Lisuride is an anti-Parkinson drug chemically related to the dopaminergic ergoline Parkinson's drugs. Lisuride binds to the 5-HT(1A) and 5-HT(2A/2C) receptors. It is also thought to bind to the dopamine receptor and to act as a dopamine agonist. Evidence has also emerged that Lisuride also binds to the Histamine H1 receptor. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target35
shared target4
shared target1

Medical side effects []

61 side effects listed on drug labels in (lisuride).

  • Decreased appetite
  • Anxiety
  • Mental disorder
  • Infection
  • Confusional state
  • Feeling abnormal
  • Cough
  • Dehydration
  • Dizziness
  • Dyspnoea
  • Erythromelalgia
  • Asthenia
  • Fatigue
  • Gastrointestinal disorder
  • Hallucination
  • Headache
  • Cardiac disorder
  • Cardiac valve disease
  • Hyperprolactinaemia
  • Orthostatic hypotension
  • Immune system disorder
  • Libido increased
  • Disturbance in sexual arousal
  • Mediastinal disorder
  • Myoclonus
  • Nervous system disorder
  • Nightmare
  • Mental disorder due to a general medical condition
  • Palpitations
  • Pathological gambling
  • Pericardial effusion
  • Pericarditis
  • Pleural effusion
  • Pleurisy
  • Pulmonary fibrosis
  • Retroperitoneal fibrosis
  • Hyperhidrosis
  • Tachycardia
  • Angiopathy
  • Vertigo
  • Vomiting
  • Weight increased
  • Weight decreased
  • Dry mouth
  • Oedema peripheral
  • Malnutrition
  • Constipation
  • Abdominal discomfort
  • Disorientation
  • Aggression
  • Peripheral coldness
  • Hypersexuality
  • Blood pressure increased
  • Dementia
  • Binge eating
  • Syncope
  • Insomnia
  • Sudden onset of sleep
  • Regurgitation
  • Pleural fibrosis
  • Somnolence

Indications

  • Acromegaly
  • Akinesia
  • Amenorrhoea
  • Bradykinesia
  • Dyskinesia
  • Galactorrhoea
  • Growth hormone overproduction
  • Hypokinesia
  • Increased prolactin level
  • Infertility
  • Nausea
  • Neoplasm
  • Parkinson's disease
  • Parkinsonism
  • Parkinsonism post encephalitic
  • Pituitary tumour
  • Prolactinoma
  • Rigors
  • Tremor

 []

  • Brazil: Lisuride is a C1.[3]
  • Other: Lisuride is a Rx-only.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 28864, Lisuride. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/28864
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Lisuride. UNII: E0QN3D755O. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/E0QN3D755O
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 03:05:44
drugspromissing (no DrugsPRO reagent data)2026-11-20 03:05:40
erowidmissing (no Erowid substance of that name)2026-11-20 03:05:40
gsrsok2026-11-20 03:05:41
hmdbmissing (hmdb.ca refused automated access to HMDB0014727)2026-11-20 03:05:40
keggok2026-11-20 03:05:42
pubchemok2026-11-20 03:05:40
redditmissing (no r/tripreports posts mention it)2026-11-20 03:05:40
siderok2026-11-20 03:05:40
structureok2026-11-20 03:05:40
wikipediaok2026-11-20 03:05:41